Investegate |SOTIO Biotech Announcements | SOTIO Biotech: SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

Investegate announcements from SOTIO Biotech, SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

Related Keywords

Czech Republic ,United States ,Switzerland ,Richard Sachse ,Michael Tattory ,Peter Grell ,Richard Kapsa ,Merck Co Inc ,Merck Sharp Dohme ,Lifesci Communications ,Masaryk Memorial Cancer Institute ,Drug Development Of Gustave Roussy Cancer Center ,Superagonist Technology ,First Patient ,Chief Medical Officer ,Managing Director ,Inpatient Unit ,Drug Development ,Gustave Roussy Cancer Center ,Merck Sharp ,Investegate Announcements ,Investegate Company Announcements ,Sotio Biotech ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,